Cargando…

Cardiovascular Disease in Rheumatoid Arthritis: Risk Factors, Autoantibodies, and the Effect of Antirheumatic Therapies

OBJECTIVE: To scope the current published evidence on cardiovascular risk factors in rheumatoid arthritis (RA) focusing on the role of autoantibodies and the effect of antirheumatic agents. METHODS: Two reviews were conducted in parallel: A targeted literature review (TLR) describing the risk factor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fazeli, Mir Sohail, Khaychuk, Vadim, Wittstock, Keith, Breznen, Boris, Crocket, Grace, Pourrahmat, Mir-Masoud, Ferri, Leticia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246480/ https://www.ncbi.nlm.nih.gov/pubmed/34262386 http://dx.doi.org/10.1177/11795441211028751

Ejemplares similares

Comparative Effectiveness of Abatacept vs. Tofacitinib in Rheumatoid Arthritis Patients who are CCP+
por: Harrold, Leslie R., et al.
Publicado: (2023)

The Effect of Massage on the Cardiac Autonomic Nervous System and Markers of Inflammation in Night Shift Workers: a Pilot Randomized Crossover Trial
por: Fazeli, Mir Sohail, et al.
Publicado: (2020)

Health state utility values by cancer stage: a systematic literature review
por: Pourrahmat, Mir-Masoud, et al.
Publicado: (2021)

Atherosclerotic Cardiovascular Disease in Rheumatoid Arthritis: Impact of Inflammation and Antirheumatic Treatment
por: Kerola, Anne Mirjam, et al.
Publicado: (2021)

Benefits of Autoantibody Enrichment in Early Rheumatoid Arthritis: Analysis of Efficacy Outcomes in Four Pooled Abatacept Trials
por: Michaud, Kaleb, et al.
Publicado: (2023)

Genetic Polymorphisms Associated with Rheumatoid Arthritis Development and Antirheumatic Therapy Response
por: Mikhaylenko, Dmitry S., et al.
Publicado: (2020)

Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients
por: Judge, Andy, et al.
Publicado: (2017)

Antirheumatic therapy is associated with reduced complement activation in rheumatoid arthritis
por: Nguyen, Thao H. P., et al.
Publicado: (2022)

Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs
por: Sokka, Tuulikki, et al.
Publicado: (2008)

Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2013)

Antirheumatic treatment is associated with reduced serum Syndecan-1 in Rheumatoid Arthritis
por: Deyab, Gia, et al.
Publicado: (2021)

Subsequent Cardiovascular Events Among Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis: Patterns of Disease‐Modifying Antirheumatic Drug Treatment
por: Sparks, Jeffrey A., et al.
Publicado: (2019)

Utilization Patterns of Disease-Modifying Antirheumatic Drugs in Elderly Rheumatoid Arthritis Patients
por: Jin, Xue-Mei, et al.
Publicado: (2014)

Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis
por: Xia, Yunfei, et al.
Publicado: (2016)

Thyroid Autoimmunity and Function after Treatment with Biological Antirheumatic Agents in Rheumatoid Arthritis
por: Bliddal, Sofie, et al.
Publicado: (2017)

The Efficacy of Biological Disease-modifying Antirheumatic Drugs on Sarcopenia in Patients with Rheumatoid Arthritis
por: Hasegawa, Eriko, et al.
Publicado: (2023)

Prescribing Trend of Antirheumatic Drugs in Taiwan and Risk of Cardiovascular Disease in Patients with Rheumatoid Arthritis: A Nationwide Cohort Study
por: Lee, Chien-Ying, et al.
Publicado: (2019)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
por: Smolen, Josef S, et al.
Publicado: (2010)

Use of Disease-modifying Antirheumatic Drugs After Cancer Diagnosis in Rheumatoid Arthritis Patients
por: Joo, Young Bin, et al.
Publicado: (2022)

Monotreatment With Conventional Antirheumatic Drugs or Glucocorticoids in Rheumatoid Arthritis: A Network Meta-Analysis
por: Guski, Louise S., et al.
Publicado: (2023)

Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naïve, early rheumatoid arthritis
por: Plein, Sven, et al.
Publicado: (2020)

Autoantibodies in rheumatoid arthritis and their clinical significance
por: Steiner, Günter, et al.
Publicado: (2002)

New autoantibodies in early rheumatoid arthritis
por: Charpin, Caroline, et al.
Publicado: (2013)

Autoantibodies to Posttranslational Modifications in Rheumatoid Arthritis
por: Burska, Agata N., et al.
Publicado: (2014)

The Clinical Value of Autoantibodies in Rheumatoid Arthritis
por: Bugatti, Serena, et al.
Publicado: (2018)

The role of autoantibodies in the pathophysiology of rheumatoid arthritis
por: Derksen, V. F. A. M., et al.
Publicado: (2017)

Therapeutic implications of autoantibodies in rheumatoid arthritis
por: Aletaha, Daniel, et al.
Publicado: (2016)

Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis
por: Kivitz, Alan, et al.
Publicado: (2014)

Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia
por: Fletcher, Ashley, et al.
Publicado: (2022)

The effect of disease-modifying antirheumatic drugs on sleep and quality of life in older patients with rheumatoid arthritis
por: Azizli, Ali, et al.
Publicado: (2023)

Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
por: Cho, Soo-Kyung, et al.
Publicado: (2023)

Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study
por: van Halm, Vokko P, et al.
Publicado: (2006)

Autoantibodies to BRAF, a new family of autoantibodies associated with rheumatoid arthritis
por: Charpin, Caroline, et al.
Publicado: (2010)

Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies
por: Song, Y.W., et al.
Publicado: (2010)

Natural autoantibodies reactive with glycosaminoglycans in rheumatoid arthritis
por: György, Bence, et al.
Publicado: (2008)

Autoantibodies in normals – the value of predicting rheumatoid arthritis
por: Dörner, Thomas, et al.
Publicado: (2004)

The Spectrum and Clinical Significance of Autoantibodies in Rheumatoid Arthritis
por: Castelar-Pinheiro, Geraldo da Rocha, et al.
Publicado: (2015)

Autoantibodies in Rheumatoid Arthritis – Laboratory and Clinical Perspectives
por: Rönnelid, Johan, et al.
Publicado: (2021)

Functional Analysis of Autoantibody Signatures in Rheumatoid Arthritis
por: Milchram, Lisa, et al.
Publicado: (2022)

Antirheumatic effects of humanized anti-Fas monoclonal antibody in human rheumatoid arthritis/SCID mouse chimera
por: Matsuno, H, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_n4pnfqso1jpee136aikmfefqt6